Biogen Aducanumab - Search Videos

FDA approves Biogen Alzheimer's drug, first new therapy for the disease in nearly two decades

FDA approves Biogen Alzheimer's drug, first new therapy for the disease in nearly two decades

The U.S. Food and Drug Administration just approved Biogen's new Alzheimer's drug Aducanumab, a historic move as it is the first new therapy for the disease in nearly two decades. The drug will be marketed under the name Aduhelm and is expected to generate billions of dollars in revenue for Biogen.

CNBCKatie TsaiJun 7, 2021

Biogen Alzheimers Drug

First new drug for Alzheimer's in 20 years approved by FDA

First new drug for Alzheimer's in 20 years approved by FDA

Biogen shares soar following promising Alzheimer's drug findings

Biogen shares soar following promising Alzheimer's drug findings

Biogen halted its Alzheimer's drug trial. Here's what that means for biotech investors

Biogen halted its Alzheimer's drug trial. Here's what that means for biotech investors

Top videos

Biogen Halts Promising Alzheimer’s Drug Trials Due to Disappointing Results

Biogen Halts Promising Alzheimer’s Drug Trials Due to Disappointing Results

TIMEJamie Ducharme

Biogen alzheimer's drug shows positive results

Biogen alzheimer's drug shows positive results

FDA panel finds Biogen's Alzheimer's drug fails to show effectiveness

FDA panel finds Biogen's Alzheimer's drug fails to show effectiveness

Biogen Stock Analysis

Biogen has been an 'uninvestable' stock for awhile, says Mizuho's Jared Holz

Biogen has been an 'uninvestable' stock for awhile, says Mizuho's Jared Holz

Investors should have known better to blame Biogen for Alzheimer's drug failure, says WSJ reporter

Investors should have known better to blame Biogen for Alzheimer's drug failure, says WSJ reporter

Biogen stock rises on sales of groundbreaking Alzheimer's drug

Biogen stock rises on sales of groundbreaking Alzheimer's drug